Characterization of a Novel Trypanosome Lytic Factor from Human Serum

JAYNE RAPER,1,* RAMIE FUNG,1 JORGE GHISO,2 VICTOR NUSSENZWEIG,2 AND STEPHEN TOMLINSON2

Departments of Medical and Molecular Parasitology1 and Pathology,2 New York University Medical School, New York, New York 10010

Received 27 May 1998/Returned for modification 27 July 1998/Accepted 2 December 1998

Natural resistance of humans to the cattle pathogen Trypanosoma brucei brucei has been attributed to the presence in human serum of nonimmune factors that lyse the parasite. Normal human serum contains two trypanolytic lytic factors (TLFs). TLF1 is a 500-kDa lipoprotein, which is reported to contain apolipoprotein A-I (apoA-I), haptoglobin-related protein (Hpr), hemoglobin, paraoxonase, and apoA-II, whereas TLF2 is a larger, poorly characterized particle. We report here a new immunoaffinity-based purification procedure for TLF2 and TLF1, as well as further characterization of the components of each purified TLF. Immunoaffinity-purified TLF1 has a specific activity 10-fold higher than that of TLF1 purified by previously described methods. Moreover, we find that TLF1 is a lipoprotein particle that contains mainly apoA-I and Hpr, trace amounts of paraoxonase, apoA-II, and haptoglobin, but no detectable hemoglobin. Characterization of TLF2 reveals that it is a 1,000-kDa protein complex containing mainly immunoglobulin M, apoA-I, and Hpr but less than 1% detectable lipid.

African trypanosomes are unicellular eukaryotic protozoa that infect both animals and humans. They are usually transmitted by the bite of the tsetse fly, and they live in the bloodstream of their mammalian hosts. The trypanosome continuously evades the immune system, systematically changing its surface coat by switching expression among a thousand distinct genes encoding the variant surface glycoprotein (6). Neverthe-

...
under 8 ml of 0.9% NaCl. The lipoproteins were then centrifuged at 49,000 rpm (228,306 × g) for 3 h at 10°C (NVTi 65 rotor; Beckman); HDL was harvested as a yellow band in the center of the tubes (p = 1.10 to 1.25 g/ml). The original infranates containing TLF2 (p = 1.27 to 1.3 g/ml) were pooled to yield 56 ml. Both TLF1 and TLF2 pools were dialyzed against three changes of Tris-buffered saline (TBS; 50 mM Tris-HCl, 150 mM NaCl [pH 7.5]) at 4°C and then concentrated by ultrafiltration (XM500 filter membrane; Amicon). TLF1 was concentrated to 1 ml (50 mg of protein/ml) and TLF2 was concentrated to 20 ml (200 mg/ml). To preserve trypanolytic activity, these concentrated protein samples were stored at −80°C until used for further purification.

The HDL preparation (2 ml containing TLF1 was fractionated by size on a Superose 6 column (1.5 by 60 cm; Pharmacia, Piscataway, N.J.) at a flow rate of 0.4 ml/min. Trypanolytic fractions (450 to 650 kDa) were pooled and concentrated. The TLF2 preparation was fractionated in 10 runs by loading 2 ml on a Superose 6 column (1.5 by 60 cm) at a flow rate of 0.4 ml/min. Trypanolytic activity (700 to 1,200 kDa) was pooled and concentrated. To preserve trypanolytic activity, these concentrated TLF samples were stored at −80°C until used for further purification. The remaining purification steps, affinity, and sizing were performed in 1 day, and lytic activity was analyzed. Freezing and thawing of the final samples resulted in a 50% loss of TLF1 lytic units and a 90% loss of TLF2 lytic unit/onarround.

An affinity column was prepared by covalently coupling a MAB raised against human Hp (H-6395, a mouse immunoglobulin G1 [IgG1] from Sigma, St. Louis, Mo.) via amino groups to a HighTrap N-hydroxysuccinimide column as instructed by the manufacturer (Pharmacia). The TLF pools were pumped onto the column in TBS at room temperature and allowed to bind for 10 min. Following washing with TBS (5 column volumes), the bound fraction was eluted with 100 mM glycine–150 mM NaCl (pH 3.0). Collected fractions (1 ml) were immmunoprecipitated using 20 ml of Immunolite (I-0140; Sigma), using 3-cyclohexylamino-1-propanesulfonic acid (pH 11) containing 10% (vol/vol) methanol. Membranes were stained with Coomassie blue, and the protein bands were excised and sequenced on a model 477A protein sequencer (Applied Biosystems) as described elsewhere (80).

Depletion of IgM and IgG from NHS. NHS was diluted twofold and incubated at 4°C for 90 min with 50 µl of either agarse-linked goat anti-human IgM (A-9935; Sigma), agarose-linked goat anti-human IgG (A-3545; Sigma), or TBS. The agarose beads were removed by centrifugation, and the supernatants were evaluated for trypanolytic activity by microscopic analysis. The thoroughness of IgM depletion was analyzed by immunoblotting the supernatants with an anti-IgM MAB (I-6385; Sigma).

Enzyme-linked immunosorbent assay. Levels of IgM and apoA-I were measured by using a standard sandwich enzyme-linked immunosorbent assay technique (9). Monoclonal anti-IgM (I-6385; Sigma) and anti-apo-A-I (MAB10; Chemicon) antibodies were used as capture antibodies (coating concentration, 10 µg/ml), and polyclonal rabbit anti-IgM (I-0140; Sigma) and goat anti-apo-A-I (AB740; Chemicon) antibodies were used as reporting antibodies. Alkaline phosphatase-conjugated secondary antibodies (Sigma) were used for detection.

**RESULTS**

### Purification of TLF1 and TLF2

TLF1 and TLF2 were purified by a four-step procedure (Tables 1 and 2). The TLFs were first separated from each other by density gradient centrifugation (see Materials and Methods for details). TLF1, which is a form of HDL, had a buoyant density predominantly of 1.20 to 1.25 g/ml, whereas TLF2 equilibrated at 1.28 g/ml (results not shown).

**TLF1.** The HDL fraction containing TLF1 showed a 50-fold increase in total activity relative to serum. This is due to the removal of the TLF1 inhibitor Hp (32, 38), most of which partitions into the infranate. The HDL was then subjected to immunoaffinity chromatography on a column containing an immobilized MAB to human Hp. This antibody also recognizes Hp. A 70-fold increase in specific activity, most likely due to the removal of nonlytic HDL, was observed in the eluate. The small amount of contaminating Hp (free and complexed with

<table>
<thead>
<tr>
<th>Sample Protein</th>
<th>Activity (U)</th>
<th>Sp act (U/mg)</th>
<th>Purification (fold)</th>
<th>Recovery (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HDL</td>
<td>100</td>
<td>100,000</td>
<td>100</td>
<td>50</td>
</tr>
<tr>
<td>Affinity column</td>
<td>0.5</td>
<td>35,000</td>
<td>70,000</td>
<td>9,400</td>
</tr>
<tr>
<td>Supercase 6HR</td>
<td>0.3</td>
<td>35,000</td>
<td>117,000</td>
<td>8,190</td>
</tr>
</tbody>
</table>

* Adjusted to allow for the removal of Hp, an inhibitor of TLF1, at the first stage of purification.

**TABLE 2. Purification of TLF2**

<table>
<thead>
<tr>
<th>Sample Protein</th>
<th>Activity (U)</th>
<th>Sp act (U/mg)</th>
<th>Purification (fold)</th>
<th>Recovery (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whole serum, 100 ml</td>
<td>7,000</td>
<td>2,000</td>
<td>0.29</td>
<td>1.0</td>
</tr>
<tr>
<td>Infranate</td>
<td>4,000</td>
<td>2,000</td>
<td>0.5</td>
<td>1.8</td>
</tr>
<tr>
<td>Supercase 6*</td>
<td>75</td>
<td>3,260</td>
<td>43</td>
<td>148</td>
</tr>
<tr>
<td>Affinity column</td>
<td>3</td>
<td>2,500</td>
<td>830</td>
<td>2,860</td>
</tr>
<tr>
<td>Supercase 6HR*</td>
<td>0.6</td>
<td>983</td>
<td>1,600</td>
<td>5,520</td>
</tr>
</tbody>
</table>

* 700- to 1,200-kDa region.

* The apparent increase in activity upon size fractionation is due to the presence of residual TLF1 (~1%) in the infranate, which becomes separated from the 96-well microtiter plate. The leading edge of the TLF1 peak at 450 to 650 kDa contaminates the TLF2 peak.

* This final size separation of TLF2 from Supercase 6HR (high resolution) is more effective due to the low amount of protein (3 mg) applied to the column compared to the initial size fractionation (Supercase 6 preparative), in which a large amount of protein was applied (400 mg). It also separates contaminating Hp and albumin (~50% protein).
nonlytic HDL) was removed by size fractionation in the final step of purification. The final preparation had a specific activity more than 8,000-fold greater than that of serum, and the recovery was 35%.

TLF2. The Hp content in the serum used for this purification scheme was 270 μg/ml. An Hp concentration of 200 μg/ml was sufficient to inhibit all of the TLF1 activity equivalent to that found in 1 ml of serum. Therefore, for the purpose of calculating specific activities and recoveries, we assumed that all of the trypanolytic activity in serum was TLF2 mediated (32). This assumption was corroborated by the recovery of an equivalent amount of lytic activity in the lipoprotein-free infranate relative to that observed in whole serum. The infranate was then concentrated and sized on a Superose 6 column in order to separate TLF2 from Hp (90 kDa). The pooled 700- to 1,200-kDa region had a total lytic activity about twice that of the infranate. This was due to TLF1 contamination in the infranate, which was masked due to the presence of Hp in the infranate. After passage through the Sepharose column, TLF1 (450 to 650 kDa) becomes separated from free Hp and its activity is unmasked. Thus, the leading edge of TLF1 contaminates the lagging edge of TLF2 (700 to 1,200 kDa). The pooled TLF2 was then subjected to immunooaffinity chromatography, and the contaminating TLF1 was removed by repurification on Sepharose 6HR column. The resulting fractions yielded a purification of 5,500-fold and a recovery of 49% relative to the activity of TLF2 in whole serum.

The purification and yields of TLF1 and TLF2 during various steps of the fractionation are shown in Tables 1 and 2, respectively. By this procedure, a 100-ml aliquot of serum yielded 300 μg of purified TLF1 and 600 μg of purified TLF2 within 4 to 5 days. In other experiments, affinity purification was performed with polyclonal antibodies to Hp, but the yields of TLF1 and TLF2 were more than 20-fold lower (data not shown). As is usually the case with polyclonal antibodies, the avidity of binding the antigen is much higher than that for MAbs, and even more extreme elution conditions can fail to release the immunogen. Despite complete binding of TLF to the polyclonal antibody column, we were unable to elute the TLF in an active form. Evaluation of the purified preparations in trypamolytic assays revealed that TLF1 lytic unit of activity is equivalent to ~10 ng of TLF1 and ~600 ng of TLF2. Based on the recovery of lytic units, NHS contains ~10 μg of TLF1 per ml (1,000 lytic units) that are inhibited by Hp and ~12 μg of TLF2 per ml (20 lytic units).

PAGE and protein sequencing of TLF1 and TLF2. Purified TLF1 and TLF2 were analyzed by SDS-PAGE. Silver-stained gels revealed that both TLF1 and TLF2 contained proteins of 40, 36, 28, and 13.5 kDa (Fig. 1). TLF2 additionally had several unique bands: a prominent 85-kDa protein, and less prominent 40, 36, 28, and 13.5 kDa bands (Fig. 1). TLF2 additionally had several bands which were not TLF1. Hpr bands in lanes 4, 6, and 7) and would therefore appear as one band on the silver-stained gel. We sometimes detect paraoxonase in TLF1 lytic activity remains unclear. We detect a trace of apoA-II in highly purified TLF1 by Western blot analysis (Fig. 2A), but anti-apoA-II antibodies failed to immunodeplete trypanolytic activity. However, the same anti-apoA-II antibodies are able to immunodeplete lytic activity from less pure TLF1 preparations (data not shown). Together these data suggest that TLF1 (like HDL) is heterogeneous in nature, and although some TLF1 particles may contain apoA-II, the lipoprotein is not required for lytic activity. Lanes 3 to 5 have peak lytic activity, and correspond to the TLF1 analyzed by the silver-stained gel in Fig. 1. The paraoxonase comigrates with Hp because they have the same molecular weight (see clear zone in center of Hp bands in lanes 4, 5, and 6) and would therefore appear as one band on the silver-stained gel. We sometimes detect paraoxonase in TLF1 by Western blot analysis, although paraoxonase does not correlate with TLF1 lytic activity. The role, if any, of paraoxonase in TLF1 lytic activity remains unclear. We detect a trace of apoA-II in highly purified TLF1 by Western analysis (Fig. 2A), but anti-apoA-II antibodies failed to immunodeplete trypanolytic activity. However, the same anti-apoA-II antibodies are able to immunodeplete lytic activity from less pure TLF1 preparations (data not shown). Together these data suggest that TLF1 (like HDL) is heterogeneous in nature, and although some TLF1 particles may contain apoA-II, the lipoprotein is not required for lytic activity. Lanes 6 to 9 represent the Hp-containing HDL that copurifies on the affinity column. This has negligible lytic activity despite the presence of Hpr; this most likely results from inhibition by the coeluting Hp. There is substantially more (~10-fold) paraoxonase and apoA-II in the HDL peak than in the TLF1 peak.

Figure 2B represents the final purification profile of TLF2.
through Superose 6HR, revealing the presence of Hpr, apoA-I, and IgM comigrating as a single peak; there was no trace of paraoxonase or apoA-II. Lanes 4 to 6 have peak lytic activity.

Chemical analysis of TLF2 did not reveal the presence of lipid components, in contrast to TLF1, which is composed of 40% lipid (11). This is consistent with the buoyant density of each particle: 1.28 g/ml for TLF2 and 1.21 to 1.25 g/ml for TLF1. In a previous study, Hb was detected in a preparation of TLF1 (4). We did not detect Hb in purified TLF2, and Hb in TLF1 is considered a contaminant (see Table 3 and Discussion). Recent analysis also indicates that Hb is not a component of TLF1 (25).

**Immunodepletion of TLF1 and TLF2 trypanolytic activity.**

To ascertain whether the identified proteins that purify with TLF2 represent integral components of the lytic factor, antibodies against each TLF2-associated protein were tested for the ability to immunodeplete lytic activity. Control immunodepletion experiments were performed with TLF1. Although protein G beads alone do not immunodeplete activity, a MAb to human Hp, which cross-reacts with Hpr (43), immunodepleted lytic activity from both purified TLF2 and TLF1 (Fig. 3). A polyclonal antiseraum to human apoA-I totally depleted TLF2 but not from TLF1 (Fig. 3).

**Immunoprecipitation of TLF components.** To substantiate that IgM, apoA-I, and Hpr proteins were associated in a single TLF2 protein complex, we investigated whether IgM was immunoprecipitated by antibodies to apoA-I and Hpr. As shown in Fig. 4, antibodies recognizing either Hp (and therefore Hpr) or apoA-I coprecipitated the vast majority of the IgM. The IgM remaining in the supernatant after incubation with anti-Hp may be a contaminant, as there was no detectable Hpr in the supernatant (not shown). IgM that does not coprecipitate with anti-apoA-I may reflect TLF2 in which the apoA-I epitopes are masked, because both Hpr and apoA-I (not performed in these immunoprecipitation studies, none of them completely remove TLF2 activity; this may reflect inaccessibility of apoA-I in a fraction of the TLF2 particles. In contrast, MABs to human IgM μ chain immunodepleted lytic activity from TLF2 but not from TLF1 (Fig. 3).

**FIG. 2.** Western blot of fractions from final step of purification of TLF1 (A) and TLF2 (B). Superose 6HR fractions encompassing molecular mass ranges of 650 to 200 kDa for TLF1 (A, lanes 1 to 9) and 1,200 to 700 kDa for TLF2 (B, lanes 1 to 9) were reduced in sample buffer. The polypeptides were separated by SDS-PAGE prior to transfer to PVDF membranes. The blots were sequentially immunoblotted with antibodies raised against apoA-I, apoA-II, Hp and Hpr, paraoxonase, and IgM as indicated on LHS. The blots were stripped between each immunoblotting step by incubation in 0.2 M glycine (pH 2.8). The black arrow corresponds to that in Fig. 1. Lanes 10, haptoglobin standard.

**FIG. 3.** Immunodepletion of TLF activity. Protein G beads (50 μl) were preincubated with 100 μg of the various antibodies. Following washing, 1 to 2 lytic units of TLF was added to the beads and incubated for 60 min at 4°C. The supernatants were then tested for trypanolytic activity. Shown are lytic activities of TLF2 (solid bars) and TLF1 (hatched bars) remaining after no addition (control) and after immunoprecipitation with protein (prot.) G beads only, anti-Hp MAB, goat anti-apoA-I polyclonal (PC) antibody, and anti-IgM MAB.

**FIG. 4.** TLF2 is a protein complex. One microgram of TLF2 was immunoprecipitated by antibodies to human Hp (MAB; α-Hp), human apoA-I (polyclonal antibodies from sheep and goat; α-apoA-I), and human IgM (MAB; α-IgM). Following immunoprecipitation, the pellet (P) and supernatant (S) were separated by reducing SDS-PAGE (12% gel) and transferred to PVDF membranes. The IgM μ chain was detected with rabbit anti-IgM μ-chain antibody followed by goat anti-rabbit IgG-HRP and exposed for 30 s by ECL.
shown) as well as residual lytic activity (Fig. 3, column 5) are found in the supernatant. The 45-kDa band recognized by the polyclonal antiserum to the IgM chain most likely corresponds to a proteolytic fragment of IgM shown in Fig. 1 and 2B (black arrows); this polyclonal antiserum does not cross-react with Hp, which migrates at about 40 kDa (Fig. 4, last lane). This finding confirms that TLF2 is a protein complex containing IgM, Hpr, and apoA-I.

**Analysis of TLF2 proteins in serum fractions.** To directly examine the cofractionation of the identified components with lytic activity, fractions of NHS separated by gel filtration were analyzed for IgM, Hpr, apoA-I, and parasite lysis (Fig. 5). Serum IgM fractionated as a single peak corresponding to the expected molecular weight of IgM pentamers. Although lytic TLF2 fractions and IgM-containing fractions overlapped, the TLF2 peak did not coincide with the IgM peak (Fig. 5a), consistent with the notion that only a subfraction of IgM is trypanolytic. The larger molecular weight of TLF2 than of the bulk of IgM is consistent with our findings that TLF2 is a complex composed of a single pentameric IgM unit bound to apoA-I and Hpr. Further analysis of serum fractions revealed the coincidence of TLF2, apoA-I, and Hpr peaks (Fig. 5). The correlation of Hpr concentration with TLF1 and TLF2 lytic activity has been reported previously (16). The sharp drop in TLF1 lytic activity at fraction 22, despite the presence of Hpr and apoA-I in subsequent fractions, is due to cofractionation of inhibitory Hp (32, 38, 43).

**Immunodepletion of IgM and TLF2 trypanolytic activity from serum.** We have previously hypothesized that the primary trypanolytic activity in unfractionated NHS is due to TLF2, because TLF1 activity is largely or completely masked by inhibition with endogenous Hp (9). The identification of IgM as a component that is unique to TLF2 relative to TLF1 provides an independent means to evaluate this observation through immunodepletion of NHS with anti-IgM. Figure 6 shows that immunodepletion with agarose-linked anti-IgM removes ~80% of the trypanolytic activity from human serum, while depletion with agarose-linked anti-IgG had a minimal effect. Western blot analysis revealed that a small residual fraction of IgM was not removed from NHS by immunodepletion, even upon repeated incubations of serum with anti-IgM agarose (data not shown). Although the explanation for this is unknown, other experiments showed that the residual lytic activity in the IgM-depleted serum was not inhibited by further addition of 250 μg of Hp per ml (data not shown). These data show that TLF2 is the main trypanolytic factor in human serum.

**DISCUSSION**

Characterization of highly purified TLF2 revealed that it is a protein complex containing mainly IgM, apoA-I, Hpr, and a small amount of Hp (Fig. 1 and Table 3). Our analysis of TLF1 revealed apoA-I and Hpr (Fig. 1) as the main proteins as well as the presence of a small amount of paraoxonase, apoA-II, and Hp (Fig. 2). It is possible that Hp is a contaminant that

<table>
<thead>
<tr>
<th>Character</th>
<th>TLF1</th>
<th>TLF2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mol wt</td>
<td>500,000</td>
<td>1,000,000</td>
</tr>
<tr>
<td>% Lipid</td>
<td>40</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Hpr</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>ApoA-I</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>IgM</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>Paraoxonase/arylesterase&lt;sup&gt;a&lt;/sup&gt;</td>
<td>&lt;20 ng/2 μg</td>
<td>&lt;20 ng/4 μg</td>
</tr>
<tr>
<td>ApoA-H&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Trace detected</td>
<td>Not detected</td>
</tr>
<tr>
<td>Inhibited by Hp</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Hb&lt;sup&gt;c&lt;/sup&gt;</td>
<td>22 ng/μg</td>
<td>&lt;1 ng/1.8 μg</td>
</tr>
</tbody>
</table>

<sup>a</sup> Paraoxonase, 0.000012 U/μg of HDL; arylesterase, 0.00003 U/μg of HDL; no activity was detected in 1 μg of TLF1 or 1.8 μg of TLF2. Paraoxonase protein was not detected in TLF2 (4 μg) by antiparaoxonase MAb F41F2-K, which has a limit of detection of 20 ng. Paraoxonase protein was detected in TLF1 at a level estimated to be 10-fold less than that detected in HDL; 1 μg of HDL contains ~70 ng of paraoxonase.

<sup>b</sup> Not detected by silver stain or Coomassie blue stain; trace amounts were detected by ECL Western blotting.

<sup>c</sup> Limit of detection of 1 ng by immunoblot with polyclonal goat anti-human Hb (Sigma). Hb detected in TLF1 cofractionates with Hpr but not Hpr or lytic activity (~500 kDa) in the final size fraction of purification, which may represent contaminating Hp-Hb complexes of ~150 kDa.

---

**FIG. 5.** Analysis of TLF2 component proteins in serum fractions. NHS was fractionated by size exclusion chromatography, and collected fractions were assayed for trypanolytic activity (a) and indicated proteins (a and b).

**FIG. 6.** Trypanolytic activity of IgM- and IgG-depleted NHS. Error bars show means ± standard deviation (n = 3).
copurifies with TLF by the anti-Hp affinity purification method. The IgM associated with TLF2 (12 μg/ml) represents a small fraction of total IgM in serum (500 to 1,900 μg/ml). We have made several attempts to remove all of the lytic activity from human serum by immunodepletion of the IgM. As shown in Fig. 6, immunodepletion of serum with anti-IgM removes ~80% of the activity. However, immunoblotting of the depleted supernatant revealed that we are unable to completely deplete the sample of IgM. The nature of the remaining 20% lytic activity is uncertain, although the residual activity is not inhibited by added Hp and therefore may correspond to TLF2. In any case, these results confirm that the main trypanolytic activity in serum is due to TLF2.

Although IgM was previously observed in partially purified preparations of TLF2, it was considered a contaminant (15). This notion was fostered from work by Rifkin (34), who used an anti-IgM serum to deplete human IgM with no decrease in trypanocidal activity. In contrast, Aaronovitch and Terry (1) concluded that the active trypanolytic factor in NHS was IgM because a rabbit antiserum to human IgM strongly inhibited the trypanocidal activity. The discrepancy in their results could be explained if the serum used by Rifkin was from an individual with low endogenous Hp levels such that TLF1 was active (see fractionation of LDL-free serum in Fig. 6A of Rifkin’s report) [34].

The presence of apoA-I and Hpr in both TLF1 and TLF2 suggests that both components play a role in trypanolytic or in the assembly of the tryptic particles. Although lytic activity in fractionated serum does not correlate with the concentration of apoA-I (Fig. 5), serum from an individual with familial apoA-I deficiency was not trypanolytic (29), suggesting that apoA-I is required. However, TLF activity could have been masked. In addition, the levels of Hp or Hp were not assessed in this patient. In contrast, sera from patients with Tangiers disease, in which levels of apoA-I are dramatically lowered, were found to be trypanolytic (42), which raised questions about the role of apoA-I in trypanolysis. As sera of patients with Tangiers disease have low levels of HDL (2 to 3%) (45), immunoprecipitation of all of the HDL with antisera against apoA-I would better address the role of apoA-I in TLF.

Evidence that Hpr may confer lytic activity comes from the observation that sera of only some apes and Old World monkeys have trypanolytic activity (37); these primates possess an Hpr gene, whereas all other animals studied to date do not (24). The exception is chimpanzee serum, which is not trypanolytic, probably due to a frameshift mutation in the Hpr sequence resulting in premature termination of translation (24). Additionally, the levels of both Hp and trypanocidal activity (13) are elevated in plasma from full-term pregnant women. We find that the lytic activity of TLF1 and TLF2 correlates with Hp concentration (Fig. 2 and 4 and reference 43).

Purified TLF1 and TLF2 have specific activities of ~10 and ~600 ng/lytic units, respectively. Compared on a molar basis, 1 lytic unit contains 18-fold more TLF2 (1,000 kDa) than TLF1 (500-KDa protein in 500-KDa particle). The immunofluorinity-based purification of TLF1 yielded a 13- to 25-fold increase in specific activity relative to preparations obtained by other purification methods (10, 39). TLF1 is labile at 4°C, and the discrepancy between specific activities may partially reflect the more rapid purification procedure used here (4 versus 8 days). In contrast to previous reports (10, 11, 39), immunofluorinity-purified TLF1 contained no detectable paraoxonase and apoA-II by silver staining or sequencing, although low levels are observed in TLF1 fractions by a more sensitive immuno-

**ACKNOWLEDGMENTS**

This work was supported in part by National Institutes of Health grants to J.R. (A141233) and S.T. (A140206) and by UNDP/World Bank grants to J.R. (A141233) and S.T. (A140206) and by the UNDP/World Bank.
REFERENCES


sional electrophoresis of plasma lipoproteins: recognition of new apo A-I


1995. Expression of inflammatory regulation of haptoglobin gene in adipo-

Wisniewski, and B. Frangione. 1993. The cerebrospinal fluid soluble form of
Alzheimer’s amyloid beta is complexes to SP-40,40 (apolipoprotein J), an
30.


E. M. Tyler, and J. D. Esko. 1989. Lysis of Trypanosoma brucei by a toxic

11. Hawking, F. 1973. The differentiation of Trypanosoma rhodesiense from
527.


13. James, R. W., D. Hochstrasser, J. D. Tissot, M. Funk, R. Appel, F. Barja,
C. Pelligrini, A. F. Muller, and D. Pometta. 1988. Protein heterogeneity
of lipoprotein particles containing apolipoprotein A-I without apolipoprotein
A-II and apolipoprotein A-I with apolipoprotein A-II isolated from human

levels of haptoglobin in biological fluids. J. Immunoassay 11:503–517.

of haptoglobin-related protein and apolipoprotein AI are components of the two
hapto-

Kunitake, S. T., K. J. La Sala, and J. P. Kane. 1985. Apolipoprotein A-I-
containing lipoproteins purified by selected affinity immunosorption. Bio-


18. Seed, J. R., J. B. Sechelski, and M. R. Loomis. 1990. A survey for a trypano-
cidal factor in primate sera. J. Protozool. 37:393–400.

Acad. Sci. USA 92:10262–10266.


tionally active haptoglobin-related (Hpr) gene in hepatoma G2 and leukemia


M. R. Rikitfin, S. Ohtaki, and V. Nussenzweig. 1995. High-density lipopro-
tein-independent killing of Trypanosoma brucei brucei by human serum. Mol.

lobin-related protein and apolipoprotein AI are components of the two
tryan-

of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and

Kasteleim, J. Geisel, J. T. Real, R. Miccoli, G. Noseda, G. Hobbel, and G.
Assmann. 1998. Plasma and fibroblasts of Tangier disease patients are dis-
turbed in transferring phospholipids onto apolipoprotein A-I. J. Lipid Res.
39:987–998.

27. Wray, W., T. Boulikas, V. P. Wray, and R. Hancock. 1981. Silver staining of

Chemnitius. 1987. Lipoproteins and hydrolysis of organophosphorus com-

Editor: J. M. Mansfield